Infilea (Clobetasol Propionate)

Clobetasol Propionate is a potent topical corticosteroid that targets inflammatory skin disorders.

• Psoriasis: reduces plaque thickness and scaling, improving skin appearance.
• Eczema: alleviates itching and redness by suppressing local immune activity.
• Dermatitis: diminishes inflammation and lesions for faster symptom relief.
• Lichen planus: controls papular eruptions and associated discomfort.

• Clobetasol Propionate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action up‑regulates anti‑inflammatory proteins such as annexin‑1 and down‑regulates pro‑inflammatory cytokines, chemokines, and adhesion molecules, leading to reduced leukocyte infiltration, edema, and epidermal hyperproliferation in the treated skin, and stabilizes lysosomal membranes, further contributing to the anti‑inflammatory effect overall in the affected area.

Topical application of clobetasol propionate may be associated with local and systemic adverse reactions.

Common Side Effects

• Skin irritation: mild burning, stinging, or itching at the application site.
• Dryness: excessive skin dryness or flaking.
• Erythema: transient redness of the treated area.
• Folliculitis: inflammation of hair follicles.
• Pruritus: worsening of itching in some patients.

Serious or Rare Side Effects

• Skin atrophy: thinning of the epidermis with possible striae formation.
• Telangiectasia: visible small blood vessels on the skin surface.
• Hypothalamic‑pituitary‑adrenal (HPA) axis suppression: systemic effects with extensive use.
• Secondary infection: bacterial, fungal or viral infection of compromised skin.
• Allergic contact dermatitis: hypersensitivity reaction to the formulation.

When prescribing clobetasol propionate, clinicians should consider several safety precautions to minimize risks.

• Duration of therapy: limit use to the shortest effective period, typically not exceeding two weeks for continuous treatment.
• Application area: avoid large surface areas or occlusive dressings unless directed by a physician.
• Age restrictions: use with caution in children under 12 years and in the elderly due to increased skin sensitivity.
• Systemic absorption: monitor for signs of systemic corticosteroid effects when applied to extensive or broken skin.
• Pre‑existing conditions: avoid in patients with uncontrolled diabetes, hypertension, or active infections without medical supervision.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Clobetasol propionate can interact with other medications or substances that affect corticosteroid activity or skin absorption.

Major Interactions (Avoid)

• Systemic corticosteroids: concurrent use may increase risk of systemic glucocorticoid adverse effects.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise local drug levels, enhancing potency and side‑effect risk.
• Antiviral agents (e.g., acyclovir): topical steroids may reduce antiviral efficacy in viral skin infections.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use may increase skin irritation.
• Immunosuppressants (e.g., methotrexate): monitor for additive immunosuppression.
• Phototherapy: may enhance skin thinning; adjust treatment intervals accordingly.